Central to our mission, we develop and commercialize oral therapies utilizing our proprietary delivery platform technology to reduce the burden of chronic injections for people with rare diseases.
Pipeline Expansion Leveraging TPE® Technology
Chiasma plans to employ its validated TPE® technology to expand its pipeline of oral therapeutic options for patients with rare diseases to use in place of painful and burdensome injections.
We are developing octreotide capsules for the maintenance treatment of acromegaly in adults – a rare, serious chronic disease.
Our clinical trials are designed to assess the safety and effectiveness of our therapies.